These data suggest that RAS overexpression does not recapitulate the effect of ERBB2 overexpression on metastatic potentials of prostate cancer cells and that ERBB2 increases metastatic potentials independent of H-RAS activation. The gene discussed is HRAS; the disease is prostate carcinoma.